邁瑞醫療(300760.SZ):一季度實現營收93.73億元 同比增長12.06%
格隆匯4月26日丨邁瑞醫療(300760.SZ)公佈2024年第一季度報吿,報吿期實現營業收入93.73億元,較上年同期增長12.06%;歸屬於上市公司股東的淨利潤31.60億元,較上年同期增長22.90%;歸屬於上市公司股東的扣除非經常性損益的淨利潤30.37億元,同比增長20.08%;基本每股收益2.6107元。
公司繼續保證高研發投入,2024年第一季度研發投入10.30億元,佔營業收入的比重達到10.99%,產品不斷豐富,持續創新迭代,尤其在高端領域不斷實現突破。2024年第一季度,在體外診斷領域,公司面向全球推出了CL-2600i全自動化學發光免疫分析儀、BS-1000M全自動生化分析儀、M680全自動生化免疫流水線、BC-20Vet三分類動物血液細胞分析儀等新產品,面向國際市場推出了胃泌素17(G-17)測定試劑盒、異常凝血酶原(PIVKA-II)測定試劑盒、弓形蟲TOXOIgG親合力測定試劑盒2項、鉅細胞病毒CMVIgG親合力測定試劑盒等新產品。在醫學影像領域,公司推出了中高端台式機Resona/NuewaI9精英版,中高端台式機Resona/NuewaI8等新產品。在生命信息與支持領域,公司推出了A3/A1麻醉系統、4K三維電子胸腹腔內窺鏡系統、動物AniFMI1輸液泵及Veta3X麻醉機等新產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.